Rani Therapeutics
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | <1m | 2.7m | - | - | - | - | 20.0m |
% growth | (53 %) | 488 % | - | - | - | - | - |
EBITDA | (15.9m) | (51.5m) | (62.2m) | (62.0m) | (53.8m) | (63.8m) | (35.5m) |
% EBITDA margin | (3440 %) | (1896 %) | - | - | - | - | (178 %) |
Profit | (16.7m) | (8.3m) | (30.6m) | (34.0m) | (28.4m) | (32.2m) | (27.4m) |
% profit margin | (3615 %) | (307 %) | - | - | - | - | (137 %) |
EV / revenue | - | 118.6x | - | - | - | - | 2.7x |
EV / EBITDA | - | -6.3x | -1.2x | -0.6x | -1.5x | -1.3x | -1.5x |
R&D budget | 12.0m | 26.5m | 36.6m | 39.6m | - | - | - |
R&D % of revenue | 2607 % | 975 % | - | - | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Series B | ||
$15.5m | Series C | ||
N/A | Late VC | ||
$39.0m | Series D | ||
N/A | Seed | ||
* | $53.0m | Late VC | |
N/A | $69.0m | Series E | |
N/A | $73.0m | IPO | |
* | N/A | $45.0m | Post IPO Debt |
* | N/A | $10.0m | Post IPO Equity |
Total Funding | AUD279m |
Related Content
Recent News about Rani Therapeutics
EditRani Therapeutics is a pioneering company in the healthcare sector, focusing on the innovative delivery of biologic drugs. Biologics are complex medications made from living organisms, often used to treat chronic diseases. Traditionally, these drugs are administered through injections, which can be painful and inconvenient for patients. Rani Therapeutics has developed a groundbreaking technology that converts these injectable drugs into oral capsules, making it easier for patients to take their medication.
The company operates in the biopharmaceutical market, targeting a wide range of chronic conditions such as diabetes, rheumatoid arthritis, multiple sclerosis, and more. Their primary clients include healthcare providers, pharmaceutical companies, and patients suffering from these chronic diseases. By offering an alternative to injections, Rani Therapeutics aims to improve patient compliance and overall quality of life.
Rani Therapeutics' business model revolves around the commercialization of their unique oral delivery platform. They generate revenue through partnerships with pharmaceutical companies, licensing their technology, and eventually selling their proprietary capsules. The company has conducted extensive preclinical studies, demonstrating that their oral capsules are as effective as traditional subcutaneous (under the skin) injections.
In summary, Rani Therapeutics is revolutionizing the way biologic drugs are delivered, making treatment more accessible and less invasive for millions of patients. Their innovative approach has the potential to transform the biopharmaceutical landscape and significantly impact patient care.
Keywords: Biologics, Oral Delivery, Chronic Diseases, Diabetes, Rheumatoid Arthritis, Multiple Sclerosis, Pharmaceutical Partnerships, Patient Compliance, Innovative Technology, Healthcare.